Investigation of the Therapeutic Efficacy of Codelivery of psiRNA-Vascular Endothelial Growth Factor and pIL-4 into Chitosan Nanoparticles in the Breast Tumor Model

Basit Öğe Kaydı
dc.authoridŞALVA, EMINE/0000-0002-1159-5850
dc.authoridAlan, Saadet/0000-0003-2329-151X
dc.authorideren, fatih/0000-0001-8126-2413
dc.authoridSalva, Emine/0000-0002-1159-5850
dc.authorwosidŞALVA, EMINE/CAH-3062-2022
dc.authorwosid/AAD-1704-2020
dc.authorwosidAlan, Saadet/ABH-4282-2020
dc.authorwosideren, fatih/AAS-6286-2020
dc.authorwosidSalva, Emine/ABI-2766-2020
dc.contributor.authorSalva, Emine
dc.contributor.authorTuran, Suna O.
dc.contributor.authorKabasakal, Levent
dc.contributor.authorAlan, Saadet
dc.contributor.authorOzkan, Naziye
dc.contributor.authorEren, Fatih
dc.contributor.authorAkbuga, Julide
dc.date.accessioned2024-08-04T20:38:03Z
dc.date.available2024-08-04T20:38:03Z
dc.date.issued2014
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAngiogenesis has been known to increase tumor growth and for its metastatic potential in human tumors. Vascular endothelial growth factor (VEGF) plays an important role in tumor angiogenesis and is a promising therapeutic target for breast cancer. VEGF is an essential target for RNAi-based gene therapy of breast cancer. Interleukin-4 (IL-4) may act as an anti-angiogenic molecule that inhibits tumor growth and migration in rats. The purpose of the present study was to improve therapeutic efficacy in breast cancer with the codelivery of siRNA-expressing plasmid targeting VEGF and IL-4-expressing plasmid encapsulating into chitosan nanoparticles (NPs). The codelivery of psiVEGF and pIL-4 plasmids greatly enhanced in vitro and in vivo gene-silencing efficiency. For the in vitro study, when psiVEGF and pIL-4 into chitosan NPs were combined (81%), the gene-silencing effect was higher than psiVEGF and pIL-4 NPs alone. The in vivo study breast tumor model demonstrated that the administration of coencapsulation of psiVEGF and pIL-4 into chitosan NPs caused an additive effect on breast tumor growth inhibition (97%), compared with containing NPs psiVEGF or pIL-4 alone. These results indicate that chitosan NPs can be effectively used for the codelivery of pIL-4 and siVEGF-expressing plasmid in a combination therapy against breast cancer. (c) 2013 Wiley Periodicals, Inc.en_US
dc.description.sponsorshipMarmara University Scientific Research Projects Association [SAG-D-100413-0124]en_US
dc.description.sponsorshipThis study was supported by Marmara University Scientific Research Projects Association (SAG-D-100413-0124). We would like to thank Prof. Dr. Jun-Ichi Miyazaki for kindly providing the pIL-4.en_US
dc.identifier.doi10.1002/jps.23815
dc.identifier.endpage795en_US
dc.identifier.issn0022-3549
dc.identifier.issn1520-6017
dc.identifier.issue3en_US
dc.identifier.pmid24357345en_US
dc.identifier.scopus2-s2.0-84894437179en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage785en_US
dc.identifier.urihttps://doi.org/10.1002/jps.23815
dc.identifier.urihttps://hdl.handle.net/11616/96354
dc.identifier.volume103en_US
dc.identifier.wosWOS:000331392900002en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofJournal of Pharmaceutical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectRNA interferenceen_US
dc.subjectVEGFen_US
dc.subjectIL-4en_US
dc.subjectchitosan nanoparticlesen_US
dc.subjectbreast canceren_US
dc.titleInvestigation of the Therapeutic Efficacy of Codelivery of psiRNA-Vascular Endothelial Growth Factor and pIL-4 into Chitosan Nanoparticles in the Breast Tumor Modelen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu